GlycoVaxyn

Schlieren, Switzerland Founded: 2004 • Age: 22 yrs Acquired By GSK
Bioconjugate vaccines for bacterial infections are developed using proprietary technology.

About GlycoVaxyn

GlycoVaxyn is a Healthcare company based in Schlieren (Switzerland) founded in 2004 by Michael Wacker, and was acquired by GSK in February 2015. Bioconjugate vaccines for bacterial infections are developed using proprietary technology. GlycoVaxyn has raised $32.12 million across 4 funding rounds from investors including Edmond de Rothschild, GSK and Index Ventures. Its chief executive, as recorded, is Philippe Dro. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial.

Company details

Founded in 2004 and based in Schlieren, Switzerland, bioconjugate vaccines are developed by the company to address bacterial infections. A proprietary glycoprotein technology is employed to produce these vaccines in bacterial cells, bypassing chemical conjugation methods. Operations focus on a portfolio of prophylactic and therapeutic options for common severe infections, within the biotechnology sector targeting vaccine innovation.

  • Headquarters Schlieren, Switzerland
  • Founders Michael Wacker
  • Stage Acquired
  • Sectors
    Healthcare
  • Website glycovaxyn.com
  • Social LinkedIn
  • Acquired by GSK (Feb 2015)
Key Metrics
  • Total Equity Funding
    $32.12M (USD)

    in 4 rounds

  • Latest Funding Round
    $22M (USD), Series B

    Mar 2009

  • Investors
  • Acquired by
    GSK

    (Feb 2015)

Funding Insights of GlycoVaxyn

GlycoVaxyn has successfully raised a total of $32.12M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $22 million completed in March 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $32.12M
  • Total Rounds 4
  • Last Round Series B β€” $22M
  • First Round $817,000

    (Jul 2006)

  • Investors Count 3

All 4 funding rounds of GlycoVaxyn with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2009$22MSeries B–Edmond de Rothschild
Feb 2009Series A––
–
Jul 2007$9.3MSeries A–Index Ventures, Sofinnova Partners
–
Jul 2006$817,000Seed–Index Ventures, Sofinnova Partners
–
Valuation history

4 investors in total: 4 institutional.

Investors in GlycoVaxyn

GlycoVaxyn has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Edmond de Rothschild, GSK and Index Ventures.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital investments in technology startups and entrepreneurs.
indexventures.com
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors
1953edmond-de-rothschild.comParis, France
Sofinnova Partners is focused on life sciences and healthcare investments.
sofinnovapartners.comParis, France
Developer of pharmaceuticals and vaccines for various therapeutic areas
1715gsk.comBrentford, United Kingdom
Premium access

Investor details for GlycoVaxyn

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of GlycoVaxyn

2 people are tracked at GlycoVaxyn (2 in leadership).

NameRoleGroup
Michael Wacker
Co-FounderLeadership
Philippe Dro
CEOLeadership
Premium access

Complete people profiles for GlycoVaxyn

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of GlycoVaxyn

4 dated milestones of GlycoVaxyn across 11 years, from founding to its latest funding, stage changes and deals.

  1. Founded GlycoVaxyn is founded.
  2. Funding First funding round of $817K.
  3. Funding Latest funding round, Series B, of $22.0M.
  4. Exit Acquired by GSK.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Glycovaxyn

GlycoVaxyn Raises $22 Million - PE Hub
Pehub β€’ 17 years ago
GlycoVaxyn Raises Series A - PE Hub
Pehub β€’ 19 years ago
Premium access

Complete news archive for GlycoVaxyn

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about GlycoVaxyn

GlycoVaxyn was founded in 2004 and raised its 1st funding round 2 years after it was founded.

GlycoVaxyn is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.

Philippe Dro is the CEO of GlycoVaxyn, as recorded in our data.

GlycoVaxyn is a funded company, having raised a total of $32.12M across 4 funding rounds to date. The company's 1st funding round was a Seed of $817K, raised on Jul 2006.

Founded in 2004 and based in Schlieren, Switzerland, bioconjugate vaccines are developed by the company to address bacterial infections. A proprietary glycoprotein technology is employed to produce these vaccines in bacterial cells, bypassing chemical conjugation methods. Operations focus on a portfolio of prophylactic and therapeutic options for common severe infections, within the biotechnology sector targeting vaccine innovation.

GlycoVaxyn has 4 investors. Key investors include Edmond de Rothschild, GSK, Index Ventures, and Sofinnova Partners.

Yes. GlycoVaxyn was acquired by GSK in February 2015.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available